In vitro transporter assay
INTRODUCTION
Hepatic transporter proteins mediate the transport of many molecules through the hepatocyte, from the blood stream into the bile. Among the membrane transporters expressed on the basolateral membrane of hepatocytes, OATP1B1, OATP1B3 and NTCP play an important role in the uptake of both xenobiotics -such as drugs and their metabolites -and endogenous compounds -such as bile acids and bilirubin. [1] [2] [3] Alteration of the functionality of these transporters may affect distribution and clearance of drugs and cause accumulation of toxic endogenous compounds in the blood. 4 Canalicular transporters such as MATE1, MRP2, BCRP, BSEP and P-gp (MDR1/3), expressed on the apical membrane of hepatocytes, mediate the biliary excretion of drugs, drug metabolites and endogenous compounds. Inhibition of the canalicular efflux transporters can result in the accumulation of toxic metabolites in the hepatocyte, causing drug induced liver disease. 5 Among the uptake transporters, the organic anion transporter polypeptide OATP1B1 (SLCO1B1, also called OATP-C) is a particularly important liver specific transporter involved in the hepatic uptake of a wide range of clinically relevant drugs. 1, 6 According to recent studies on the absolute quantitative determination of the amount of transporters in the human liver, OATP1B1 is the most abundant uptake transporter. 7 OATP1B1 downregulation, inhibition or genetic polymorphism may lead to inter-individual pharmacokinetic alterations and potential drug-drug interactions (DDIs). 8 Conversely, the sodium taurocholate co-transporting polypeptide NTCP, (SLC10A1), appears to be involved in the uptake of a relatively small number of clinically used drugs, but inhibition of NTCP can be a contributing factor to DDIs and a reduced NTCP activity or expression can result in a depressed bile acid uptake leading to cholestasis and hyperbilirubinemia. 3, 9, 10 On the other hand, the efflux transporter BSEP (bile salt export pump, ABCB11), mediates the excretion of bile acid salts from the apical membrane of hepatocytes to the bile canaliculi. 9, 11 Reduced activity of this transporter can be involved in drug induced liver injury caused by the accumulation of toxic bile acids in hepatocytes. [12] [13] [14] Imaging of hepatic transporters activity has produced interesting data that contributed to increase the understanding of DDI's pharmacokinetics and proved the role of membrane transporters in drug distribution and disposition of some important clinically used drugs. Recently, review articles have been published which provide extensive information on general aspects, such as ideal criteria of Positron Emission Tomography/Computed Tomography (PET/CT) probes, design of hepato-selective PET probes, case studies, strengths and weaknesses of PET in imaging of transporters. 15 PET tracers which are actively transported across cellular membranes can be used as probes to study membrane transport in vivo by imaging the tracer's uptake. In principle, any transport inhibition of the tracer would alter its in vivo distribution, which in turn could be used to determine the DDI potential of investigational drugs capable of inhibiting the tracer's transport pathways mediated by the transporter protein(s) involved. Bile acids -which are endogenous compounds synthesized in the liver as final products of cholesterol metabolism and excreted in the bile of vertebrates -are obvious substrates of these important transporters, and have been extensively employed as probe compounds to study physiological and pathological conditions related to the hepatobiliary transport. [16] [17] [18] [19] In this paper we report the design and synthesis of three fluorinated bile acid derivatives 4a-c as prospective PET tracers for the imaging of OATP1B1/1B3, NTCP and BSEP activity in vivo. These compounds were labeled with tritium and assayed for in vitro transport properties. Based on the in vitro tests results, the lead compound LCATD (4c) was selected as candidate PET tracer and a fully automated radiosynthesis of [ 18 F]-4c, suitable for producing the tracer in multi-GBq scale, was developed. Finally, a pilot imaging experiment was performed in a rat to prove that the PET tracer [ 18 F]-4c is hepatocyte-directed and excreted only through the bile.
RESULTS

Synthesis of unlabeled and tritiated bile acid derivatives.
The "cold" compounds CATD, DCATD and LCATD (4a-c) were synthesized respectively from cholic acid 1a, deoxycholic acid 1b and lithocholic acid 1c, which were reacted with racemic propargyl-glycine methyl ester and HATU in the presence of diisopropylethylamine. Propargyl-glycine-conjugated bile acids 2a-c were isolated in good yields (>82%) as diastereomeric mixtures by flash column chromatography (FCC). Compounds 2a-c were then reacted with 1-azido-4-fluorobutane (obtained in turn from 1-bromo-4-fluorobutane and sodium azide in DMF) in the copper-mediated alkyne-azide cycloaddition (CuAAC) to give triazoles 3a-c in high yields and with complete regiocontrol. 20 Ester function deprotection of 3a-c with 2M KOH in methanol solution gave quantitative yield of bile acidtriazole derivatives 4a-c as inseparable mixtures of two diasteroisomers (Scheme 1). Unsuccessful attempts were made for separating the diastereomers by flash chromatography. ]-4c was also significantly higher (p < 0.01) in HEK293-OATP1B1 cells than in HEK293-MOCK cells, and for the lower concentration studied (1 and 10 μM) the difference was significant (p < 0.001). Uptake ratios were found to be between 6.5 and 11.8 for [ The net OATP1B1-mediated substrate transport (UOATP1B1) was found to be saturable for 4c and it could be described with a Michaelis-Menten equation (Fig. 3C) , whereas full saturation could not be reached for 4a,b (Fig. 3A,B) . For 4c the apparent Km and Vmax, determined by plotting UOATP1B1 (pmol min
) against substrate concentration, are reported in Table 1 . Table 1 and Fig.  4 ). Values of OATP1B1-intrinsic clearance (or intrinsic capacity) CLint, OATP1B1 and passive diffusion clearance CLdiff obtained for 4c are reported in Table 1 along with those obtained in the same cells and -as reported previously by our group 6 -for some well-known OATP1B1 probe compounds: estradiol-17-β-glucuronide, pravastatin and pitavastatin. Since the OATP1B1 mediated transport of 4c is similar to that of these OATP1B1 probes (Table 1) , this compound was selected as potential PET tracer, and its transport properties were further investigated.
Figure 4. Concentration dependent OATP1B1-mediated uptake inhibition of (A) DCATD (4b) (B) LCATD (4c) by rifamycin SV.
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CLint, OATP1B1 (µL min (Fig. 5A ). Uptake ratios were between 2.0 and 2.4 (at concentrations 10 and 100 μM respectively, Fig. 5B ). An attempt to estimate Km by measuring the OATP1B3-mediated uptake failed as the saturation of the transporter was not reached at the highest concentration studied (100 µM). In CHO-NTCP cells the uptake of [ 3 H]-4c (0.05 μM) was found to be higher than in the control cell line and linear between 1 and 10 minutes of incubation and higher than in CHO-parental cell line at any time (Fig. 6 ). Uptake ratios were between 4 and 32. The net NTCP-mediated substrate transport (UNTCP) was found to be saturable and followed a Michaelis-Menten kinetic (Fig. 7A) . Apparent Km and Vmax, determined by plotting UNTCP (pmol min
) against substrate concentration were found to be 49 μM and 2035 pmol/min/mg, respectively. 
Uptake of [
H]-LCATD (4c) in BSEP inverted vesicles
Transport of LCATD (4c) was determined in membrane vesicles transfected with BSEP transporter in the presence of ATP (total transport) and AMP (passive transport) over a concentration range 10-300 µM. The ATP dependent transport was determined by deducting the transport in the presence of ATP to that in the presence of AMP and this reflected the BSEP mediate transporter activity (pmol/min/mg). Compound 4c exhibited concentration dependent BSEP mediated transport in BSEP transfected membrane vesicles (Fig. 7B) . 
Radiosynthesis of [
F]-LCATD-4c
Compound 2c was acylated in >98% yields with acetic anhydride in anhydrous pyridine to give the alkyne 6 which was reacted with 4-azidobutanol, copper sulphate and sodium ascorbate in a water/tert-butanol mixture (1:2) to give 7 in 90% yields. The mesylation was carried out in anhydrous dichloromethane in the presence of freshly distilled triethylamine and mesyl chloride, to give the radiofluorination precursor 8. F]-4c in 25 ± 5 % (n = 5) decay corrected radiochemical yield, as a mixture of two epimers at the α-amino acid carbon. The total radiosynthesis, purification and formulation time was about 90 minutes.
Imaging results
A pilot imaging experiment with [ Fig. 8 (PET-CT). The radioactivity was primarily located in the liver with no obvious uptake in the kidneys or other organs in the abdominal region. The liver uptake and biliary excretion of radioactivity through the biliary duct was clearly visible after 1-2 minutes postinjection. At 20 minutes the radioactivity was localised mainly in the intestinal region while almost no signal was visible in the liver.
Figure 8. Images obtained for a representative control rat. At 1 min only the liver is visible. At 2 min the bile duct is clearly visible. From 5 to 25 minutes the intestine is visible because of the presence of the bile containing the radioactive tracer.
Time-activity curves (TAC) for the liver, blood and intestine are shown in Fig. 9 . The activity in the blood, deduced from the activity of the region of interest (ROI) corresponding to the abdominal aorta, rapidly decreased after 15 seconds from the injection to less than 1% after 10 min. The TAC in the liver increased linearly for the first 75 seconds post-injection, reached a peak corresponding to 12.4% of the injected dose at 165 seconds and then exponentially decreased to 1% of the injected dose after 27 minutes. The TAC for the intestine ROI reached the maximum activity (29.5 % of the injected dose) 8.75 minutes after the liver peak activity, at 11.5 minutes from the injection. After this time the activity measured in the intestine appeared to decrease, probably because of the bile flow to the lower intestine region, which was not entirely covered by the field of view of the PET scan. 
F]-4c
is not yet available, the expected metabolism for compound 4c may be similar to that of lithocholic acid: in rats hydroxylation at the position 3, 6 and 7 may occur, as well as glucuronidation of the hydroxyl group in position 3, 24 while in humans, oxidation of the hydroxyl group to ketone and hydroxylation of positions 6 and 7 may be possible (3-ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acid). 25 The labelling position is however stable, as no uptake of [
18 F]-fluoride in the bone tissue was observed in the PET-CT scan.
DISCUSSION AND CONCLUSION
In this study we synthesized three fluorinated derivatives of endogenous bile acids 4a-c as candidate probes for imaging hepatic transporters activity (Fig. 10) . The current project was focussed primarily on characterizing the in vitro transport of 4a-c by OATP1B1/1B3 because of their well-understood role in clinical DDIs, 2 but the possibility of 4a-c being transported by other uptake transporters (for example, OATP2B1, OATP1A2, OAT2, OAT7) cannot be excluded. In addition to OATP1B1/1B3, bile salt transporters (NTCP/BSEP) were also studied because of the close structural similarity of 4a-c to bile salts and hence the possibility of NTCP/BSEP being involved in their transport. The three compounds 4a-c share the same carbon-backbone but have different numbers of OH groups on the bile acid scaffold: this affects the lipophilicity of the compounds as well as their number of donor/acceptor hydrogen bonds (see Table 2 ). The bile acid derivatives 4a-c were readily prepared from commercial bile acids through a short synthetic route which also allowed the synthesis of tritium labeled compounds [ ]-cholylsarcosine has been successfully employed to image the biliary excretion in pigs, with potential applications in the study of pathophysiological conditions of the liver such as inherited cholestasis , acquired liver disease, acute hepatitis, primary biliary cirrhosis, post-transplantation liver dysfunction, and biliary obstruction. 14, 26 However, only [
11 C]-labeled PET tracers have been developed so far to study hepatic membrane transporters, thus limiting the access to this valuable technology to PET centres with a cyclotron on site. 27 In addition, the higher activity achievable for production run and the longer half-lives of [ In order to identify and characterize the transporters involved in the hepatocyte uptake of the fluorinated bile acid derivatives 4a-c, in vitro assays were performed using the tritium labeled versions [ OATP1B3 is closely related to OATP1B1 and it is known that bile acids, bilirubin and eicosanoids are among the endogenous substrates of both OATP1B3 and OATP1B1: 11, 28 For this reason compound 4c was tested in an OATP1B3 substrate assay (Fig. 5 ). Even though significant differences were found in the uptake rates between the transporter-expressing cells and the control cells, the uptake ratio = 2 and the incomplete saturation of the transporter at 100 µM suggest that 4c is a poor substrate of OATP1B3. In fact literature data about bile acids as substrates for OATP1B3 report Km of 85.3 µM for cholic acid, and uptake ratios of 4.9 for prototypical substrates. 29 The probe compound 4c showed significant linearly time dependent uptake by NTCP-CHO cells, and uptake ratios were 4-32 (Fig. 6) . The NTCP-mediated transport of 4c in HEK293 cells was saturable and the apparent Km and Vmax were 49 µM and 2035 pmol/mg/min, respectively (Fig. 7a) . Reported value of Km for the prototypical substrate taurocholate in NTCP-CHO cells is 8.4 ± 1.3 μM 30 which suggests that the introduction of a triazole-alkyl chain substituent on the α-carbon of the glycine does not strongly affect the substrate recognition by NTCP, albeit it does reduce the affinity.
The bile acid derivative 4c was also tested as substrate of BSEP, which is the transporter involved in the efflux of bile salts from the hepatocyte and into the bile canaliculi ( Fig. 7b and 10) . Although very few drugs are known to be substrates of BSEP, this transporter can be involved in drug induced liver injury caused by the accumulation of toxic bile acids in hepatocytes: the inhibition of BSEP by certain drugs was in fact correlated to the potential of cholestatic drug induced liver injury. 31 In BSEP expressing membrane vesicles the derivative 4c exhibited concentration dependent ATP driven active transport suggesting that in vivo it might get excreted in bile. Our data indeed suggest that derivative 4c is a substrate of BSEP, which can play a role in the in vivo excretion of 4c from the hepatocyte into the bile.
Differences in uptake and efflux of compounds 4a-c could be analysed in light of their lipophilicity and number of donor/acceptor hydrogen bonds. Estimation of the lipophilicity of the endogenous bile acid conjugates and bile acid-triazole derivatives is provided in Compared to the endogenous bile acid conjugates, the corresponding labelled derivatives 4a-c appear to be more lipophilic and the introduction of the triazole ring increases the number of hydrogen bond acceptor atoms by 3. Difference in physicochemical properties between inhibitors and non-inhibitors of OATPs suggests that lipophilicity is positively correlated with the potential for interaction with such transporters. 32 A substrate pharmacophore for OATP1B1 has been published in 2005 (whose key pharmacophore features appear to be two hydrogen bond acceptors at either end of a large hydrophobic area) 33 however, structural information of the binding site would be required to rationalize the structure-activity relationship for the synthesized bile acid derivatives, as all of them can easily fit in the proposed pharmacophore.
The PET tracer version [ 18 F]-4c was synthesized and purified in an automated module which allowed the production of multi-GBq amount of radiotracer in good purity and yields for a pilot imaging experiment. In order to preliminarily assess the biodistribution of [ 18 F]-4c, in vivo imaging experiments were performed in a single wild type rat. Even though there is not a direct orthologue of human OATP1B1 in rats and murine OATP1B3 and NTCP transporters have shown different affinity for their substrates compared to human transporters, 1 the rat model is widely accepted for preclinical experiments aimed to assess the involvement of hepatic transporters in the clearance of drugs and radiotracers. 1, 15 The in vivo biodistribution of [
18 F]-4c was found to be liver-specific, as the tracer uptake was selective in the liver and then the tracer was excreted in the bile: no activity was detected in the kidneys or urinary bladder ( Fig. 8 and Fig. 9 ). Based on the in vitro tests, the liver uptake and excretion of [ 18 F]-4c should be mostly due to the effect of membrane transporter OATP1B1 and NTCP. The poor passive permeability of 4c, which is ionized at physiological pH, and the exclusive and fast distribution in the liver support this hypothesis. As expected, after being accumulated into the liver, the tracer is excreted into the bile via the efflux transporter BSEP, even if we cannot exclude the contribution of other efflux transporters such as MATE1, BCRP, MRP2 and PgP. The probe compound 
Experimental
Bile acids, chemicals and solvents used in the synthesis, rifamycin SV, sodium fusidate, Dulbecco's modified essential media (DMEM), Hanks' balanced salt solution (HBSS) and triton X-100 were purchased from Sigma-Aldrich UK. UltimaGold and Monoscint 20 scintillation cocktails were obtained from PerkinElmer Life and Analytical Sciences UK. Phosphate-buffered saline (without CaCl2 and MgCl2), geneticin (G418), and L-glutamine were purchased from Invitrogen, UK. Heat inactivated foetal calf serum was procured from PAA Laboratories GmbH UK. BD Biocoat™ Poly-D-lysine 24-multiwell plates were purchased from BD Biosciences (Oxford, UK MS experiments were performed on an Agilent Technologies 1200 Series HPLC system equipped with a DAD and a 6120 MS detector composed by an ESI ionization source and a Single Quadrupole mass selective detector. HRMS were performed at the National Mass Spectrometry Facility (Swansea, UK). All reactions were carried out in oven-or flame-dried glassware under nitrogen atmosphere, unless stated otherwise. All commercially available reagents were used as received. Reactions were magnetically stirred. Flash chromatography was performed on silica gel (60 Å, particle size 0.040-0.062 mm). Yields refer to chromatographically and spectroscopically pure compounds, unless stated otherwise. The radiotracer synthesis and purification was performed using a Eckert and Ziegler ModularLab system equipped with the HPLC module. The purified hot tracer and the cold reference were analysed using a Shimadzu Prominence HPLC system equipped with a PDA UV detector and HERM LB500 activity detector. Phenomenex Luna C18 column, 5 μm, 100 Å, 250 × 4.6 mm (L × ID) and Phenomenex Luna C18 column, 5 μm, 100 Å, 250 × 10.0 mm (L × ID) were used as analytical and semipreparative HPLC columns respectively.
General procedure for the synthesis of compounds 2a-c
To a mixture of bile acid (1.22 mmol) and HATU (465 mg, 1.33 mmol) in DMF (20 mL), DIPEA (1.2 mL. 4.00 mmol) was added dropwise, followed by propargyclycine methyl ester hydrochloride (217 mg, 1.33 mmol). The reaction mixture was stirred at room temperature for 3 h. Water (50 mL) was then added and HCl 2 M was used to adjust the pH= 2.5-3. The mixture was extracted with EtOAc (30 mL) and the organic phase was then washed with a saturated solution of NaHCO3 (30 mL) and brine (10mL). The organic phase was then dried over MgSO4 and the solvents removed at reduced pressure. The crude was purified via FCC using DCM/MeOH (15:1) as a mobile phase. *)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10 
Methyl 2-((R
Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)pent-4-ynoate (2b)
White amorphous solid, in 82% yield. 
Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)pent-4-ynoate (2c)
White amorphous solid, in 92% yield. 
General procedure for the synthesis of compounds 3a-c
1-Bromo-4-fluorobutane (155 mg, 1 mmol) was dissolved in DMF (0.5 mL) and NaN3 was added (98 mg, 1.5 mmol). The mixture was stirred overnight. Et2O (1 mL) and H2O (1mL) were added and the organic layer was transferred to a suspension of alkyne 2 (0.5 mmol) in tBuOH/H2O (2:1, 3 mL). CuSO4 (8 mg, 0.05 mmol) and sodium ascorbate (30 mg, 0.15 mmol) were added and the reaction mixture was stirred for 48 hours at room temperature. Saturated NH4Cl (10 mL) was added, the mixture was extracted with EtOAc (3X 10 mL) and the organic phase was dried over MgSO4, solvents were removed under reduced pressure and the crude product was purified by FCC (DCM/MeOH gradient from 15:1 to 10:1).
methyl 3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)-2-((R*)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoate (3a)
Prepared from alkyne 2a, white foam, 89% yield. 
Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)propanoate (3b)
Prepared from alkyne 2b, white foam, 85% yield. 
Methyl 3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)-2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoate (3c)
Prepared from alkyne 2c, white foam, 86% yield. 
General procedure for the synthesis of compounds 4a-c
The methyl ester 3 (100 mg, 0.157 mmol) was dissolved in MeOH (2 mL) and KOH 2 M (1 mL) was added. The mixture was stirred at room temperature for 3 hours, the volatile components were removed, H2O (2mL) was added and concentrated HCl was added dropwise to precipitate the acid 4.
3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)-2-((R*)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoic acid (4a), CATD
Prepared from methyl ester 3a, 96 mg, 98% yield as a white solid. R*)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl) 
3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)-2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoic acid (4c), LCATD
Prepared from the ester 3c, white solid, 98% yield. 
General procedure for the synthesis of compounds 5a-c
Alkyne 2 (0.5 mmol) was dissolved in THF (2.5 mL) and treated with N-iodomorpholine-hydrogen iodide (260 mg, 0.75 mmol) followed by CuI (10 mg, 0.05 mmol). Sample was stirred for 2 hours and after this time the suspension was poured onto a pad of neutral alumina (~10 mL) and the solution was collected under vacuum. The pad was then washed 3 times with a solution of methanol in DCM (5%, 10 mL). The volatile were evaporated to give a yellow wax. 1-fluoro-4-azidobutane (approximately 0.75 mmol, unpurified) THF (2.5 mL), CuI and (5 mg, 0.025 mmol) TEA (140 μL, 1.00 mmol) were added. The mixture was stirred at room temperature for 24 hours. After this time the reaction was quenched by adding 1 mL of 10% NH4OH solution. The crude mixture was extracted with ethyl acetate (3 X 10 mL), washed with brine, dried over MgSO4 and the volatile components were removed by evaporation. The crude was purified by FCC (DCM/MeOH gradient from 15:1 to 10:1)).
Methyl 3-(1-(4-fluorobutyl)-5-iodo-1H-1,2,3-triazol-4-yl)-2-((R*)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoate (5a)
Prepared from alkyne 2a, 300 mg, 80% yield, pale yellow foam. 3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-fluorobutyl) 
Methyl 2-((R*)-4-((
Methyl 3-(1-(4-fluorobutyl)-5-iodo-1H-1,2,3-triazol-4-yl)-2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoate (5c)
Prepared from alkyne 2c, 290 mg, 80% yield, pale yellow foam. 
Tritium labelling
Labelling with tritium was performed according to the previously reported procedure. 21 
Synthesis of precursors for radiofluorination
Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-acetoxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)pent-4-ynoate (6)
To a solution of alkyne 2c (200 mg, 0.41 mmol) in anhydrous pyridine (1 mL), acetic anhydride (78 µL, 0.82 mmol) was added. The mixture was stirred for 3 hours at room temperature. The solvent was removed under reduced pressure and the crude was dissolved in AcOEt and washed with a saturated solution of NaHCO3. The organic phase was dried over MgSO4, the solvent was removed and the product purified via FCC (Hex/AcOEt 8:2) to give the title compound as a white foam in quantitative yield (215 mg). 
Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-acetoxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-hydroxybutyl)-1H-1,2,3-triazol-4-yl)propanoate (7)
Prepared from alkyne 6 and 4-azido-1-butanol according to the general procedure for triazole synthesis in 90% yield. 14 (m, 1H), 1.21-1.26 (m, 3H), 1.29-1.45 (m, 8H), 1.49-1.57 (m, 4H), 1.65-1.87 (m, 7H), 1.93-1.96 (m, 1H), 2.02 (s, 3H), 2.06-2.13 (m, 1H), 2.21-2.30 (m, 1H) 
Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-acetoxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-(methylsulfonyloxy)butyl)-1H-1,2,3-triazol-4-yl)propanoate (8)
Compound 7 (100 mg, 0.16 mmol) was dissolved in anhydrous DCM (1 mL) at 0 °C. TEA (32 µL, 0.23 mmol) was added followed by mesylchloride (18 µL, 0.23 mmol). The reaction was stirred at 0 °C for 4 hours (complete conversion by TLC analysis). A saturated NaHCO3 solution (1 mL) was added, the mixture was extracted with DCM (2 x 3 mL) and the organic phase was dried over MgSO4. The title compound was obtained after FCC (Hex/AcOET 8:2) to give the title compound as a white foam in quantitative yield. 
Transport study
Cellular uptake of tritium labeled compounds was measured using monolayer cultures of HEK293-OATP1B1, HEK293-OATP1B3, HEK293-MOCK, CHO-NTCP and CHO parental cells grown on 24-well plates as described previously, 6, 22 with specific adaptation as described in the following sections. The tritiated test compound was diluted in HBS (pH adjusted to 7.4) to obtain 30 mL of 0.05 µM working solution (about 37 KBq mL -1 ) which was warmed to 37 °C prior to assays. Concentration dependent uptake of the potential PET tracer was studied over a range of six concentrations having activity of about 37 KBq mL -1 . The culture media was removed from the 24-well plates containing the desired cell line at about 100% confluence. Cells were washed three times (3 × 0.5 mL) with prewarmed (37 °C) HBS solution (pH adjusted to 7.4). The medium was carefully removed by aspiration using a vacuum pump. The third wash of HBS solution was left on the cells and the plate was warmed on a bench top incubator at 37 °C for 15 minutes before starting the uptake assays. The HBS solution was removed from the wells immediately prior to start of the assay. To start the uptake assay, 0.5 mL of pre-warmed test compound solution were added to the wells (experiments were performed in triplicate) by using a multipipette and the plate was returned to the bench incubator at 37 °C. At the designed time, the solution containing the test compound was carefully removed from the wells by aspiration and the cells were washed three times (3 × 1 mL) with ice-cold HBS solution (pH 7.4). Cells were lysed by adding Triton X-100 (0.5 mL, 0.1% v/v) to each well. The plates were gently shaken for 30 min at room temperature and the lysate (200 μl) was transferred into 10 mL glass scintillation vials containing Ultima Gold® scintillation cocktail (5 mL) for liquid scintillation counting. The plates containing the cell lysate were stored at -20 °C for protein analysis. The amount of protein content per well was determined as a mean of six wells per plate using the Pierce® BCA Protein assay kit. Transport of tritiated test compounds in HEK293-OATP1B1 and HEK293-MOCK transfected cells was assessed in the presence and absence of the inhibitor rifamycin SV in a range of 6-concentrations with the aim to determine IC 50 values for the inhibition of OATP1B1-mediated transport. Rifamycin SV was dissolved in DMSO to obtain a primary 10 mM stock solution which was diluted with pre-warmed HBS solution (pH 7.4) to obtain six pre-incubation solutions of rifamycin SV at 100, 10, 1, 0.1, 0.01, 0.001 μM. Content of DMSO was kept constant at 1 % (v/v). To obtain the six co-incubation solutions, the secondary stock solutions of rifamycin SV were diluted 100 times with HBS (pH adjusted to 7.4) containing 0.05 µM (37 KBq mL-1 ) of the tritiated substrate. The culture media was removed from the 24-well plates containing HEK293-OATP1B1 cells at about 100% confluence. Cells were washed three times (3 × 0.5 mL) with pre-warmed (37 °C) HBS solution (pH 7.4) and replaced by the pre-incubation solutions containing the inhibitor. The plate was incubated at 37 °C for 15 minutes. After this time, the pre-incubation solutions were removed and the uptake was initiated by adding to the working solution containing the inhibitor at 0.001, 0.01, 0.1, 1, 10, 100 μM and the labeled substrate. The plate was returned to the incubator and after 8 minutes of incubation the working solutions were removed from the wells and the cells treated as previously described.
The concentration of substrate into the cell lysate, Clysate (pmol ml where 60000 is the conversion factor between disintegration per minute (DPM) and KBq. The uptake rate U was calculated with the equation (2), where U is the rate of uptake of substrate in the cells (pmol min
); T is the time of incubation (min); P is the mean protein content (mg ml −1 ) per well; and Clysate is the substrate concentration in cell lysate (pmol ml
The net TRANSPORTER-mediated substrate transport UTRANSPORTER (pmol min
) was determined as the difference between the uptake rate in TRANSPORTER-expressing cells (UTRANSPORTER-expressing cell) and MOCK-cells (UMOCK cell) (equation 3):
The influx or uptake ratio, defined as the ratio of the uptake rate in TRANSPORTER-expressing cells (UTRANSPORTER-expressing cell) and MOCK-cells (UMOCK cell), was calculated according to equation 4and its uncertainty ( ) according to equation 5:
Where SD represents the standard deviation (n = 3). To determine if data sets obtained for the two cell lines were significantly different, Student's t-test (Microsoft® Excel 2013) was applied. GraphPad Prism (Version 6) (Michalis-Menten equation) was used to determine apparent Km and Vmax by plotting UTRANSPORTER (pmol min
) against substrate concentration. To calculate the concentration of inhibitor that produces half-maximal inhibition (IC50) of transporter activity, UOATP1B1 was plotted as a percentage of control probe substrate (100% OATP1B1 activity was assumed when no inhibitor was present) against inhibitor concentration. Transporter activity (% of control) is then calculated according to the following formula:
where z is the OATP1B1 uptake of the probe in the presence of the inhibitor, y is the OATP1B1 uptake of the probe in the absence of the inhibitor. An IC50 value was obtained using a four-parameter logistic model (XLFit 5, Model 201) or any other appropriate model if needed:
where y is the % control activity and x is the logarithm of concentration of inhibitor, a and b are the vehicle and positive control and are locked to 0 and 100, respectively; c is the IC50 and d is the Hill slope of the curve. In order to understand the contribution of passive diffusion and the contribution of specific transporter OATP1B1 in the uptake of the PET probe compounds in HEK293-OATP1B1 cells, the OATP1B1-intrinsec clearance (or intrinsic capacity) Clint, OATP1B1 and passive diffusion clearance Pdiff were calculated by (equations 8-7)
where Vmax is the maximum rate of uptake, Km is the Michaelis-Menten constant, UMOCK is the uptake measured in HEK293-MOCK cells and C is the concentration of the substrate.
Transport in BSEP-expressing membrane vesicles in the presence and absence of ATP was determined as described previously. 12, 23 Uptake solutions contained 1 % (v/v) DMSO containing the radiolabeled compound and the appropriate concentration of the corresponding non-radiolabeled compound and membrane vesicles in uptake buffer (HEPES/Tris pH 7.4: 25mM; KNO3 : 250mM; Sucrose: 125mM; Mg(NO3)2 :31mM). The 2 μl of test compound was added to the 96-well PCR assay plate followed by 50 μl of 2-fold concentrated uptake buffer with ATP or AMP. The assay plate is kept on the heating block (37°C) and incubated for 3 min. Reaction was initiated by addition of 48 μl vesicle suspension per well. After 5 min incubation time 80 μl of the reaction mixture was transferred to the filter-plate containing 150 μl stop buffer (Sucrose: 50mM; KCl: mM, 100mM; HEPES/Tris pH 7.4: 10mM; Taurocholate: 0.1 mM; EDTA pH 7.4: 5mM). Filter-plate was transferred to the vacuum manifold and vacuum applied to trap the vesicles in the filter. Washed vesicles 4 times with 150 μl stop buffer, aspirating between each washing step. Filterplate was dried over night at room temperature. 150 μl of OptimaGold F was added per well and incubated for 10 min and plate sealed with TopSeal adhesive film. Radioactivity was measured on the Microbeta2 (Perkin Elmer, UK). The mean counts per minute (CPM) from three replicate wells containing an aliquot of the original uptake solution (containing buffer and vesicles) was determined and used to calculate the CPM/pmol normalisation factor:
(equation 10)
Where:
Total CPM was the mean value of wells containing original uptake solution Total µl of aliquot was the volume of original uptake solution Total µM of radiolabeled compound was the concentration in the uptake solution prior to initiation of the incubation
The CPM of each test sample well was determined and divided by the CPM/pmol normalisation factor to calculate the amount (pmol) of compound taken up by the vesicles. This amount was divided by the incubation time (min) and the protein amount in the incubation (mg) to give the uptake activity (pmol/min/mg). Mean (n = 3 wells) net BSEP transport activity was determined by subtracting transport in BSEP-transporter vesicles in the presence of ATP to that of transport in the presence of AMP. All experiments above were performed in triplicates at single occasion. (5 mg in 0.5 mL of sterile water) and collected in the reactor, followed by the solution of Kryptofix K222 (15 mg in 1 mL of anhydrous CH3CN). A first drying cycle was accomplished by heating at 95 °C under both vacuum and helium flow (400 seconds) and then under vacuum only (150 seconds) before delivering an additional amount of anhydrous CH3CN. The drying process was repeated and the solution of mesylate precursor 8 (5 mg in 1 mL of anhydrous CH3CN) was then delivered into the reactor containing the [ 18 F]KF-K222 dry complex. The mixture was heated at 90 °C for 15 minutes. The reactor was cooled to 40 °C before adding the sodium hydroxide solution (0.5 mL, 2M in 50% aqueous methanol) which was allowed to react for 10 minutes. After the hydrolysis step, the crude reaction mixture was neutralized with 2M HCl (0.5 mL) and pumped into a vial containing the HPLC eluent (PBS/CH3CN 60:40, 1.5 mL). The mixture (about 3 mL) was then loaded in the 5 mL RP-HPLC loop and then injected in the Phenomenex Luna C18 column (5 µm, 250x10 mm, 100 Å), which was eluted with PBS/CH3CN 60:40 (5 mL min-1 flow). The peak corresponding to the desired product was collected in a vial containing 50 mL of distilled water. The diluted solution of pure [ ). The total synthesis, purification and formulation time was about 90 minutes. The tracer was obtained in 25 ± 5 % (n = 5) decay corrected radiochemical yield. HPLC analysis of the formulated product confirmed the identity (co-injection with cold reference material) and the purity of the tracer (RCP >99%). Attempts to measure the specific activity of [ 18 F]-LCATD failed due to the low UV absorbance of the tracer.
PET/CT imaging experiment-pilot study
The animal experiment was performed according to the University's Code of Practice on the Use of Animals in Research as well as the legal requirements of the Animals Act 1986 and Home Office Code of Practice guidance. PET scans were performed with a small-animal PET/CT scanner (ARGUS-Sedecal, Spain) housed in a temperature-controlled suite. The scanner has two 11.8 cm diameter rings of photoswich detectors coupled to position sensitive photomultiplier tubes, giving a 4.8 cm axial field of view (FOV). A female Sprague-Dawley (SD) rat (207g) was provided with standard food and water ad libitum in a temperature and light-controlled environment. The animal was cannulated (Venisystem Butterfly, Abbott Ireland) in the tail vein for tracer injection under general anaesthesia with isoflurane (IsoFlo 100% w/w, Abbott Laboratories Ltd) 2.5 % (2 L min-1 oxygen flow). At the start of the scan [ 18 F]-LCATD 4c (5.89 MBq) was injected as a single bolus and the administered radioactivity was measured as net counts in the cannula before and after the injection with an ionization chamber (Capintec CRC-15PET; Ramsey, New Jersey). Emission scans in 3D list-mode were acquired for 30 minutes (with a FOV encompassing part of the thorax and the intestine) followed by a 5 minutes CT scan. At the end of the imaging experiment, the animal was sacrificed under anaesthesia (neck dislocation). PET acquisitions were obtained with an energy window set to 250 -700 keV and corrections for deadtime, activity decay, attenuation, random and scatter counts were applied (using the manufacturer' software). The dynamic images were obtained by sorting the list mode data into the following time frames: 6x10s, 8x30s, 10x60s, 3x300s, and images were reconstructed with a FORE/2D-OSEM reconstruction algorithm (provided by the manufacturer). Sampling at shorter intervals during early time-points enabled to detect rapid increments of tracer uptake in the liver and intestine. Longer time frames at later time-points from the injection time showed the amounts of uptake characteristic for the specific PET tracer. Regions of interest (ROIs) corresponding to abdominal aorta, liver and gastrointestinal tract were manually drawn using PMOD software (PMOD Technologies). The stomach was included in the gastrointestinal ROI to include the amount of bile that might have refluxed from the duodenum into the stomach. Due to the limited FOV of the PET scan -which was not enough to cover the lower intestine -in this PET study the activity in the bile might be underestimated.
